Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of CE2.F
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

CE2 Dividend Payout History


# Declaration Date Ex-Date Pay Date Amount Yield
1 Jul 12, 2023 Jul 12, 2023 Jul 12, 2023 0.600€ 0%
2 Jul 13, 2022 Jul 13, 2022 Jul 13, 2022 0.450€ 0%
3 Jul 14, 2021 Jul 14, 2021 Jul 14, 2021 0.350€ 0%
4 Apr 21, 2020 Jul 15, 2020 Jul 17, 2020 0.300€ 0%
5 Mar 25, 2019 Jul 17, 2019 Jul 19, 2019 0.150€ 0%

FAQ

What is the symbol for CropEnergies AG Stock and on which exchange is it traded?
The symbol for CropEnergies AG is CE2.F and it is traded on the FRA (Frankfurt Stock Exchange).

Should I buy or sell CropEnergies AG Stock?
CropEnergies AG holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy CropEnergies AG Stock?
CropEnergies AG Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy CropEnergies AG Stock.

What's the current price of CropEnergies AG Stock?
As of the end of day on the May 15, 2024, the price of an CropEnergies AG (CE2.F) share was 11.52€.

What is the 52-week high and low for CropEnergies AG Stock?
The 52-week high for CropEnergies AG Stock is 11.60€ and the 52-week low is 6.75€.

What is the market capitalization of CropEnergies AG Stock?
As of the May 15, 2024, the market capitalization of CropEnergies AG is 1.005B.

When is the next earnings date for CropEnergies AG?
The upcoming earnings date for CropEnergies AG is Jul 10, 2024.
Click to get the best stock tips daily for free!

About CropEnergies AG

CropEnergies AG Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine,... CE2.F Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT